| Name | Title | Contact Details |
|---|
At MELA Sciences, we design and develop innovative software-driven medical technologies for physician clinical use during the detection of skin cancers at the most curable and cost-effective stages. Our mission is to develop breakthrough medical technologies to improve skin cancer detection and achieve better outcomes for all. We envision a world in which our pioneering innovations will change the way patients think about skin cancer, while providing dermatologists and clinicians with new, effective, non-invasive tools for the earliest detection possible. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature. The company’s flagship product, MelaFind®, is intended to provide dermatologists with software-driven image analysis of clinically atypical pigmented skin lesions when they choose to obtain additional information to help decide whether to biopsy or not. The FDA has approved MELA Sciences’ MelaFind® Pre-Market Approval application for use in the United States and MELA Sciences has also been granted CE Mark approval for sale of MelaFind® in the European Union.
MedAvante Inccvc is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. MedAvante Inccvc is based in Trenton, NJ. You can find more information on MedAvante Inccvc at www.medavante.net
Eastern Maine Healthcare Systems (EMHS) is committed to delivering quality and cost-effective patient care despite the difficult healthcare environment that's challenging the nation and the residents of Maine.
Calhoun Vision is focused on developing vision correction technologies for post-cataract surgery patients.
Emergent Health Corp. is a public company (trading under the symbol EMGE) dedicated to the betterment of its shareholders and product consumers. We believe we have a developing product line to become a leader in the field of Regenerative Medicine and improved neutraceuticals and phytonutritionals to be available to the general public without a prescription.